One Broadway, 14th Floor
About Tremeau Pharmaceuticals
Tremeau is a new pharmaceutical company focused on providing non-opioid treatment options for rare diseases and other unique patient conditions with no approved treatments. Tremeau’s unique approach to acute and chronic pain in rare diseases is rooted in the mechanism of action, documented efficacy, and clinically differentiated profile of COX-2 selective NSAIDs.
Founder: Mark Corrigan
CEO: Bradford C. Sippy
4 articles with Tremeau Pharmaceuticals
Opioids have shown tremendous efficacy in pain management. At the same time, the dangers of the addiction to the medication have become well-known in recent years as an epidemic has swept across the United States.
With increased worries over the addictive nature of opioid-based pain treatments, more and more companies are focusing on the development of effective treatments without the addictive nature.
Tremeau and FDA Agree on Phase III Plan for Rofecoxib as a Non-Opioid Pain Treatment for Hemophilic Arthropathy
Tremeau announced today that it has recently gained agreement with the FDA, in a formal Type B Meeting, on the development requirements to support a New Drug Application.
FDA Grants Orphan Drug Designation for TRM-201 (rofecoxib) for the Treatment of Hemophilic Arthropathy
“Tremeau’s strategy of matching rofecoxib’s profile to specific populations who can benefit from the drug is a good approach..."